# US 11,906,517 B2 · Method for diagnostics, treatment and prevention of Parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,906,517 B2
- Document ID: US11906517B2
- Status: Granted
- Kind: B2
- Application number: 17/933,952
- Filed: 2022-09-21
- Published: 2023-07-13
- Granted: 2024-02-20
- Earliest claimed: 2014-05-28
- Assignees: Neurobiome Oy
- Applicants: Neurobiome Oy
- Inventors: Filip Scheperjans; Petri Auvinen; Velma Aho; Pedro Pereira; Kaisa Koskinen; Lars Paulin
- Web page: https://patentgrep.com/patent/US11906517B2

## CPC

- G01N 33/56911: {Bacteria}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 25/16: Anti-Parkinson drugs
- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2800/2835: Movement disorders, e.g. Parkinson, Huntington, Tourette
- G01N 2800/50: Determining the risk of developing a disease
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to the field of medicine and in particular to Parkinson's disease (PD). Specifically the present invention relates to methods and means for early detection of PD. The invention relates also to methods and means for treatment or prophylaxis of PD. In the method of the invention a probability of a subject developing or having Parkinson's disease (PD) is determined by measuring the relative abundances of one or multiple microbial taxa in a sample from a subject; and the probability of the subject developing or having PD is determined based on the measured abundances. The present invention provides a novel approach for the diagnostics of PD.

## Claims

### Claim 1

A method for treatment or prevention of Parkinson's disease (PD) in an individual, comprising administering to said individual a composition that increases the abundance of Prevotellaceae in the intestine, wherein active ingredients of the composition consist of Prevotellaceae.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises live or killed microbes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is in the form of a food composition, pharmaceutical composition, nutraceutical, supplement or an anaerobical microbiota culture.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises Prevotella.

### Claim 5 (depends on 4)

The method of claim 4, wherein the composition comprises one or more Prevotella genera selected from the group consisting of Prevotella amnii, Prevotella bergensis, Prevotella bivia, Prevotella bryantii, Prevotella buccae, Prevotella buccalis, Prevotella copri, Prevotella coprocola, Prevotella disiens, Prevotella marshii, Prevotella melaninogenica, Prevotella oralis, Prevotella oris, Prevotella ruminicola, Prevotella salivae, Prevotella sp, Prevotella sp oral taxon 299, Prevotella sp oral taxon 317, Prevotella sp oral taxon 472, Prevotella tannerae, Prevotella timonensis and Prevotella veroralis.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition decreases intestinal abundance of one or more of taxa selected from the group consisting of Lactobacillaceae, Verrucomicrobiaceae, Bradyrhizobiaceae, Clostridiales Incertae Sedis IV, Ruminococcaceae, Lachnospiraceae, Enterobacteriaceae, Bacteroidaceae, Alistipes, Coprococcus, Anaerotruncus, Porphyromonadaceae, Parabacteroides, Butyricicoccus, Collinsella, Eggerthella, Coriobacteriaceae, Sporobacterium, Actinobacteria, Blautia, Enterococcus, Acetivibrio, Allobaculum, Agromonas, Firmicutes, Mahella, Phaeovibrio, Porphyromonadaceae, Oscillibacter and Saccharofermentans.

### Claim 7 (depends on 1)

The method of claim 1, wherein the individual is diagnosed with PD.

### Claim 8 (depends on 1)

The method of claim 1, wherein the individual has a high probability developing or having PD, wherein the individual has a low relative abundance of Prevotellaceae and/or Prevotella.

### Claim 9 (depends on 8)

The method of claim 8, wherein the individual has a low relative abundance of Prevotellaceae and/or a high relative abundance of one or more of taxa selected from the group consisting of Lactobacillaceae, Verrucomicrobiaceae, Bradyrhizobiaceae, Clostridiales Incertae Sedis IV, Ruminococcaceae, Lachnospiraceae, Enterobacteriaceae, Bacteroidaceae, Alistipes, Coprococcus, Anaerotruncus, Porphyromonadaceae, Parabacteroides, Butyricicoccus, Collinsella, Eggerthella, Coriobacteriaceae, Sporobacterium, Actinobacteria, Blautia, Enterococcus, Acetivibrio, Allobaculum, Agromonas, Firmicutes, Mahella, Phaeovibrio, Porphyromonadaceae, Oscillibacter and Saccharofermentans.

### Claim 10 (depends on 8)

The method of claim 8, wherein the individual is not diagnosed with PD.

### Claim 11 (depends on 9)

The method of claim 9, wherein the individual is not diagnosed with PD.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition is administered mixed in food or drink or separately in the form of a tablet, capsule, microcapsule, powder, solution or paste.

### Claim 13 (depends on 12)

The method of claim 12, wherein the food is a food supplement, a formula for nutritional purposes, or a nutraceutical, and/or wherein the food optionally contains additives and excipients.

### Claim 14 (depends on 4)

The method of claim 4, wherein the Prevotella comprises one or more species of Prevotella disiens, Prevotella oris, or Prevotella melaninogenica.

### Claim 15 (depends on 1)

The method of claim 1, wherein active ingredients of the composition consist of one or more species of Prevotella disiens, Prevotella oris, or Prevotella melaninogenica.